Sobi’s Dova Pharmaceutical Reports Results of an Online Survey Highlighting Disease Burden and Impact for Patients with Immune Thrombocytopenia

Shots:

• The online survey assesses 76 patients from the Platelet Disorder Support Association that has been diagnosed with ITP, prior treated with at least one therapy. The 30-45-min online survey is about demographics, diagnosis experience, symptoms, disease management and treatment
• Results: 58% demonstrated ITP-related fatigue interfered with their work, family, or social life; prior to-/ post-treatment, 35%/39% & 13%/16% reported fatigue daily & twice a wk.; Platelet count at diagnosis: < 10 x 109/L (47%) and 10 – 30 x 109/L (27%), at time of survey: < 30 x 109/L (4.62 %) and > 100 x 109/L (47.69%) respectively
• The survey demonstrates the complexity of ITP and the effects of fatigue, bleeding and treatment on the lives of the patients. The survey reported that 59% reported bleeding does not interfere with their work, family or social life

Click here to­ read full press release/ article | Ref: Sobi | Image: Pharmaceutical Technology